Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph not_applicable
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting150%
unknown150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingnot_applicable

Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

NCT05667597
unknownnot_applicable

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

NCT05492643

Clinical Trials (2)

Showing 2 of 2 trials
NCT05667597Not Applicable

Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

Active Not Recruiting
NCT05492643Not Applicable

The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
2